Sleep loss impairs waking functions and is homeostatically compensated in recovery sleep. The mechanisms underlying the consequences of prolonged wakefulness are unknown. The stimulant modafinil may promote primarily dopaminergic neurotransmission. Catechol-O-methyltransferase (COMT) catalyzes the breakdown of cerebral dopamine. A functional Val158Met polymorphism reduces COMT activity, and Val/Val homozygous individuals presumably have lower dopaminergic signaling in the prefrontal cortex than do Met/Met homozygotes. We quantified the contribution of this polymorphism to the effects of sleep deprivation and modafinil on subjective state, cognitive performance, and recovery sleep in healthy volunteers. Two-time 100 mg modafinil potently improved vigor and well-being, and maintained baseline performance with respect to executive functioning and vigilant attention throughout sleep deprivation in Val/Val genotype subjects but was hardly effective in subjects with the Met/Met genotype. Neither modafinil nor the Val158Met polymorphism affected distinct markers of sleep homeostasis in recovery sleep. In conclusion, dopaminergic mechanisms contribute to impaired waking functions after sleep loss.
Sleep and wakefulness form a daily continuum, yet the genetic and neurochemical mechanisms underlying sleep-wake regulation are largely unknown. Not only the clinically defined sleep disorders such as narcolepsy, obstructive sleep apnea, and behaviorally induced insufficient sleep syndrome ("sleep deprivation") but also shift work, jet lag, and voluntary sleep restriction are highly prevalent in the modern "24/7" society. In many people, non-restorative and insufficient sleep leads to excessive daytime sleepiness, which is strongly associated with the risk of accidents and human error. 1 The impact of insufficient sleep on health and well-being has developed into a major public health concern. 2 The availability of effective countermeasures to reduce sleepiness and the behavioral and cognitive consequences following sleep loss are of clinical and public importance. This fact is highlighted by the ubiquitous use of pharmacological agents to promote wakefulness and maintain alertness after insufficient sleep. Whereas caffeine is considered the most often consumed substance in the world, the stimulant modafinil, because of its apparently positive safety profile, is becoming increasingly popular.
Modafinil in daily doses of 100-400 mg is clinically used as the first-line treatment for pathological sleepiness in patients with narcolepsy. 3 Controlled studies also demonstrated its efficacy as an adjunct therapy for subjective sleepiness and fatigue in various diseases such as obstructive sleep apnea, 4 shiftwork sleep disorder, 5 Parkinson's disease, 6 major depressive disorder, 7 and multiple sclerosis. 8 Although it is certain that the pharmacological profile of modafinil differs from those of amphetamine-like compounds, there is still controversy regarding its mode of action. The available evidence ranging from data from experiments in genetically modified mice to in vitro electrophysiology suggests that the drug stimulates wakefulness primarily by modifying dopaminergic and (nor)adrenergic neurotransmission. 9 Consistent with this notion, clinical observations in narcolepsy indicate that the response to modafinil is modulated ARTICLES by a functional genetic variation in the important breakdown enzyme of cortical catecholamines, catechol-O-methyltransferase (COMT). 10 The human COMT gene is located on chromosome 22q11.2 and contains a functional single-nucleotide polymorphism (SNP) that alters the amino acid sequence of the membrane-bound COMT protein at codon 158 from valine (Val) to methionine (Met; SNP-ID: rs4680). 11 No equivalent COMT polymorphism was found in any other species examined to date, including non-human primates. 12 Europeans have nearly equal prevalence of Val (~48%) and Met (~52%) alleles, whereas the Val allele is much more common in populations from other parts of the world. 12 Individuals who are homozygous for the Val allele show more COMT protein in postmortem brain tissue than individuals with two Met alleles. 13 Moreover, Val/Val genotype subjects show three-to fourfold higher COMT activity and presumably lower dopaminergic signaling in the prefrontal cortex than do Met/Met genotype subjects. 13, 14 There is strong evidence to suggest that the Val158Met polymorphism of COMT affects the prefrontal cortex and associated areas, modulating executive functioning, working memory, and measures of attention. 15 The sleepiness in narcoleptic patients may be comparable to the sleepiness experienced by healthy subjects after 2 days without sleep. 16 Sleep loss not only increases sleepiness but also affects mood and impairs executive functions, working memory, and sustained attention. 17 Moreover, it is highly reliably compensated by enhanced non-rapid-eye-movement (non-REM) sleep intensity as measured by low-frequency (delta) electroencephalography (EEG) activity in recovery sleep. 18 A decrease in the activation and functioning of the prefrontal cortex may be critical for the waking consequences of sleep loss 19 (for recent review, see ref. 20) . While the effects of modafinil on quantitative sleep EEG measures in humans are not known, the drug improves impaired alertness and performance on cognitive tasks after 36-85 h of prolonged waking. 9, 21 Nevertheless, the subjective and objective efficacy are variable, and a return to pre-sleep-deprivation performance is not usually observed. 21, 22 We combined pharmacogenetic, pharmacokinetic, neuropsychologic, and polysomnographic methods to delineate a dopaminergic mechanism in human sleep-wake regulation. On the basis of the evidence described above, we hypothesized that sleep deprivation and modafinil affect the same neuronal processes and that the efficacy of the stimulant to reverse sleep loss-induced changes in subjective state, cognitive function, and sleep are modulated by the Val158Met polymorphism of COMT. Indeed, we found that, in Val/Val genotype subjects, modafinil potently improves vigor and subjective well-being and maintains stable performance with respect to executive function and vigilant attention throughout 40 continuous hours of wakefulness, whereas it is virtually ineffective in Met/Met genotype subjects. By contrast, modafinil does not affect well-established, wakefulness-induced sleep and sleep EEG changes in recovery sleep in subjects of either genotype. These findings show that mechanisms involving prefrontal cortex dopamine contribute to distinct aspects of impaired subjective state and cognitive performance after sleep deprivation but are not critically important for the homeostatic regulation of low-frequency delta activity in the non-REM sleep EEG.
RESULTS
Two groups of healthy men homozygous for the Val/Val (n = 10) and Met/Met (n = 12) genotypes of the functional Val158Met polymorphism of COMT were prospectively enrolled in this study (see Supplementary Data online). The groups were carefully matched for age, body mass index, habitual alcohol and caffeine consumption, anxiety (Trait Anxiety Inventory), subjective daytime sleepiness, and chronotype ( Table 1 ; for nocturnal melatonin profile, see Supplementary Figure S1 online). A screening night in the sleep laboratory demonstrated that all the participants were good sleepers with no sleep disturbances.
Modafinil concentration in saliva
Under constant supervision all volunteers completed two 40-h periods of continuous wakefulness in the sleep laboratory (Figure 1) . After 11 and 23 h of wakefulness, they received 100 mg modafinil or placebo in randomized, double-blind, crossover fashion. Prior to the drug intake, modafinil was below the limit of detection in all subjects. Whereas there was no difference between subjects with the two genotypes with respect to the pharmacokinetics of the drug after the administration of the first capsule, the maximum concentration after the second capsule occurred earlier and was higher in Val/Val allele carriers than in the Met/Met group (Figure 2) . Clearance from saliva 4 h after the second dose and the mean concentration of modafinil 1 h before initiation of recovery sleep (0.11 ± 0.01 μg/ml vs. 0.12 ± 0.01 μg/ml) were similar in the two groups.
Modafinil consistently improves subjective state after sleep deprivation in Val/Val genotype subjects only
Previous research has indicated that low-dose modafinil is not consistently associated with subjectively perceived elation or ARTICLES stimulation after sleep deprivation. 22 The subjective perception of the stimulant effects of modafinil was quantified 4 h after intake of each capsule, at the time of the expected maximum concentration of the drug in saliva. 9 The "stimulant effects score" was invariably higher after active treatment than after placebo in subjects with the Val / To examine whether the different subjective effects reflected the initially higher modafinil concentrations in Val/Val allele carriers, the Spearman rank-correlation coefficient between the mean concentration at 30 and 60 min after drug intake and the stimulant effect score after the second capsule were computed. No significant relationship emerged (r = 0.1, P = 0.63, n = 22). However, subjects with the Val/Val genotype tended to correctly assign verum and placebo capsules more often than subjects with the Met/Met genotype (90% vs. 66% correct, P = 0.09, Fisher's exact test).
Next, we analyzed the effects of sleep deprivation and modafinil on subjective symptoms of fatigue, anger, vigor, and depression, as quantified with a validated German translation of the Profile of Mood States. 23 These analyses revealed that sleep deprivation approximately doubled fatigue and slightly increased anger. Irrespective of genotype, modafinil was ineffective in mitigating these deteriorations in subjective state (data not shown). However, the drug attenuated the typical drop in 
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vigor associated with prolonged wakefulness. This effect was restricted to Val/Val genotype subjects and was completely lacking in those with the Met/Met genotype (Figure 3a) . Moreover, in both baseline and sleep-deprived states, vigor was higher in Val/Val than Met/Met allele carriers. Neither sleep deprivation nor genotype affected symptoms of depression as measured using the Profile of Mood States. Nevertheless, depression after sleep deprivation was lower in the Val/Val genotype subjects after modafinil than after placebo (Figure 3b) . The values did not differ in subjects with the Met/Met genotype. To further investigate whether modafinil differently affects subjective well-being after sleep deprivation, the objective "Befindlichkeits-Skala" of von Zerssen was used. 24 Sleep deprivation reduced well-being, whereas modafinil improved it 
in subjects with either genotype. Interestingly, the presence of two Val alleles enhanced the drug's efficacy. Subjects with the Val/Val genotype had scores similar to those at baseline after drug intake following sleep deprivation, whereas, in subjects with the Met/Met genotype, modafinil produced significantly less improvement (Figure 3c ).
Modafinil maintains cognitive performance during sleep deprivation in Val/Val genotype subjects only
Redundancy on a random-number-generation task provides a sensitive index of a subject's ability to update and monitor information. 25 This aspect of executive functioning is particularly responsive to the detrimental effects of prolonged wakefulness. 26 Compared to placebo, modafinil maintained low redundancy after sleep deprivation in subjects with either of the two genotypes (Figure 4, top panels) . Nevertheless, the drug effect was more pronounced in Val/Val subjects than in Met/Met subjects. Working memory is vulnerable to sleep loss. 17 To investigate whether modafinil affects working memory differently in Val/Val allele carriers than in Met/Met allele carriers after sleep deprivation, subjects performed a visual two-back task on days 1 and 2 of prolonged wakefulness. Irrespective of genotype, sleep deprivation reduced response speed and approximately doubled the percentage of incorrect responses ( Table 2) . Modafinil attenuated these impairments. After intake of the drug, the speed and accuracy of response in the sleep-deprived subjects no longer differed from baseline values in either genotype.
Performance on the psychomotor vigilance task (PVT) is a sensitive measure of sustained vigilant attention, which is normally impaired after prolonged wakefulness. 17 Across the first 16-20 h of wakefulness, Val/Val and Met/Met allele carriers maintained almost lapse-free, fast and stable PVT performance, under both placebo and modafinil conditions (Figure 4 , lower panels). Afterward, in the placebo condition, the number of response lapses increased and reaction times became longer and more variable. Performance was worst when testing occurred in the morning of day 2 of prolonged wakefulness. Most intriguingly, low-dose modafinil fully eliminated the wakefulnessinduced impairment of sustained vigilant attention in subjects with the Val/Val genotype (P > 0.2 for factor "session" for all PVT measures), whereas it was virtually ineffective in those with the Met/Met genotype (P < 0.0001). By contrast, the number of false responses in the absence of stimuli (sometimes referred to as "errors of commission") did not differ on the basis of either . ***P < 0.0001 (factor "condition" of two-way analysis of variance with between-factor "genotype" (Val/Val, Met/Met) and within-factor "condition" (mean baseline, SD-placebo, SD-modafinil)).
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the treatments or the genotypes (data not shown). This observation suggests that lack of motivation was not a critical factor in the reduced efficacy of modafinil in subjects with the Met/ Met genotype.
Modafinil does not affect established markers of sleep homeostasis in recovery sleep
The homeostatic facet of sleep regulation refers to the highly reliable finding in animals and humans that recovery sleep after prolonged waking occurs with reduced latency and is more intense than baseline sleep. 18 After sleep deprivation, in subjects with either genotype and irrespective of treatment, the reduction in the time taken for subjects to fall asleep and the lengthening of the duration of deep slow-wave sleep (non-REM sleep stages 3 and 4) were similar in relation to baseline values (Figure 5a,b) . Slow, rhythmic oscillations in EEG wave patterns during non-REM sleep are a well-established physiological marker of sleep need and sleep intensity. The prevalence and amplitude of oscillations in the 0.75-2.0 Hz range (low-frequency delta activity) were quantified with all-night spectral analysis in baseline as well as in recovery sleep. This frequency band most sensitively reflects the putative effects of genetic variation and caffeine on sleep homeostasis. [27] [28] [29] Sleep deprivation increased low-frequency delta activity to a similar extent of 47-50% in both Val/Val and Met/Met allele carriers (Figure 5c ). Modafinil did not affect the magnitude of this increase in either genotype. These findings demonstrate that, in contrast to subjective state and distinct aspects of cognitive performance, recovery sleep was not significantly affected by modafinil or the Val158Met polymorphism of COMT after sleep deprivation.
DISCUSSION
In this study we showed that the functional Val158Met polymorphism of COMT strongly modulates the efficacy of low-dose modafinil with respect to subjective state and cognitive performance after sleep deprivation. The study provides the first example of a pharmacological intervention that sustains high and stable waking functions throughout 2 days and 1 night without sleep in a genetically distinct group of healthy individuals. Because both the COMT Val158Met polymorphism and modafinil changes dopaminergic signaling in the prefrontal cortex, 13, 14, 30, 31 we conclude that altered dopaminergic neurotransmission contributes to impairment of well-being and cognitive performance after sleep loss. By contrast, neither COMT genotype nor modafinil were seen to affect well-established, sleep deprivation-induced changes in recovery sleep. These findings demonstrate that, in humans, the mechanisms that mediate the effects of sleep loss on waking neurobehavioral functions are different from those that mediate the effects of sleep loss on distinct characteristics of sleep physiology.
To follow the pharmacokinetics of modafinil in Val/Val and Met/Met allele carriers, we developed a novel liquid chromatography-mass spectrometry/mass spectrometry method for quantifying modafinil levels in saliva (see Supplementary Data online). Consistent with data from plasma, we found that in young men the drug is readily absorbed and peak concentration is reached at 2-4 h after oral administration. 3, 9 There was a significant genotype-associated difference in modafinil levels 1 h after the second capsule intake. One cannot exclude the possibility that this pharmacokinetic difference contributes to some modafinil-induced variations in subjective state and performance after sleep deprivation. Nevertheless, modafinil is not known as a substrate of COMT, and the time course of drug concentration in the β-phase (final three measurements) indicates that modafinil metabolism and elimination are independent of COMT genotype. Esterase enzymes in the liver are primarily responsible for the hydrolytic deamination of the drug to modafinil acid, and cytochrome P450 (CYP) 3A4 converts this inactive metabolite to modafinil sulfone. 9 However, modafinil is a substrate of P-glycoprotein, which is encoded by the multidrug resistance gene MDR1 and which inhibits and induces, respectively, the human CYP isoenzymes 2C19 and 3A4/5. The genes of these proteins are polymorphic and play important roles in mediating interindividual differences in absorption and metabolism of drugs. One cannot exclude the possibility that the distribution of alleles and genotypes in MDR1 and CYP isoenzymes differ between Val/Val and Met/Met allele carriers. The possibility that polymorphisms in these genes interact with the Val158Met polymorphism of COMT and modulate the pharmacodynamics and pharmacokinetics of modafinil is intriguing and warrants further investigation.
Low-dose modafinil does not reliably enhance cognitive task performance in non-sleep-deprived subjects. 32, 33 Similarly, the drug's efficacy to reduce subjective and objective measures of sleepiness after sleep deprivation differs widely among individuals. 22 Our data provide the first demonstration that the Val158Met polymorphism of COMT contributes to these interindividual differences in healthy adults. Two-time 100 mg modafinil, the lowest recommended dose in narcolepsy, consistently improved subjective state and maintained executive functioning and vigilant attention throughout 40 h of continuous wakefulness in subjects with the Val/Val genotype but was virtually ineffective in those with the Met/Met genotype. Based on the hypothesis that this genetic variation affects synaptic dopamine levels in the prefrontal cortex, 13 our data suggest that prefrontal cortex dopamine is critically involved in subjective and objective impairment from sleep deprivation. Frontal brain structures and associated functions are especially vulnerable to the effects of sleep loss. 20 Medial frontal and prefrontal structures, together with the anterior cingulate cortex and the thalamus, are important for emotional processing, executive functions, and attentional control. 34 Modafinil increases blood flow in these cerebral regions in highly functional states 35 as well as in impaired cognitive states, such as after sleep loss. 36 The recruitment of cortical and subcortical activation by modafinil may primarily reflect dopaminergic effects, 30, 31, 37 although other mechanisms are also involved. 9 It had earlier been proposed that COMT genotype modulates the response of the prefrontal cortex to higher levels of dopamine according to an inverted U-shaped response curve. 38 Our observations are compatible with this hypothesis. They suggest that the drug efficiently mitigates impaired subjective state and cognitive performance after sleep loss in Val/Val ARTICLES genotype subjects who, exhibit relatively deficient dopamine signaling. By contrast, the drug is barely effective in Met/Met genotype subjects who, have relatively higher dopaminergic tone at synapses where COMT activity is critical.
An important impact of the Val158Met polymorphism of COMT on daytime functioning was previously found in patients with narcolepsy. Specifically, a sex-related dimorphism and a strong effect of genotype on disease severity were reported. 39 Women narcoleptics with high COMT activity fall asleep twice as fast during the multiple sleep latency test (3 min) than those with low COMT activity (6 min). An opposite relationship, although less pronounced (5.6 min vs. 4.1 min), is observed in men. 39 An inspection of patient histories revealed that the response to treatment with modafinil to control excessive daytime sleepiness also differs between COMT genotypes. Patients (both female and male) with the Val/Val genotype need a higher daily dose (329.2 mg) than patients with the Met/Met genotype (241.0 mg). 10 A comparison of these data with our findings is difficult because different outcome variables and subject populations were studied. Nevertheless, COMT genotype may distinctly modulate the individual response to modafinil in narcolepsy patients undergoing long-term pharmacotherapy and in healthy men after acute drug administration. This notion is supported by functional brain imaging data showing that a 4-week intake of modafinil decreases cerebral blood flow in fronto-temporal cortices in narcoleptic patients, 40 whereas no such decrease is observed after single-dose administration in healthy volunteers. 35 The reasons for this discrepancy are unknown.
Previous reports postulate that the sleep rebound following modafinil-induced wakefulness is reduced or even absent compared to the sleep rebound after sleep deprivation. 41, 42 Although there is some controversy regarding this finding, 43 it suggests that modafinil could compensate for changes in the brain that are the physiological consequences of prolonged wakefulness. These changes are reliably and predictably reflected in recovery sleep, in the form of shortened sleep latency, prolonged slow-wave sleep, and increased slow rhythmic oscillations in non-REM sleep EEG. 18 These can normally be reversed only by sleep. Modafinil had no effect on recovery sleep in either Val/Val subjects (who maintained baseline levels of executive functioning and sustained attention throughout 40 h without sleep) or Met/Met subjects (who showed wakefulness-induced impairment in waking functions). These observations challenge the hypothesis that modafinil inhibits the homeostatically regulated increase in deep non-REM sleep duration and intensity following prolonged wakefulness. In addition, the data suggest that the effects of sleep loss on daytime functioning and on the sleep EEG are separately regulated.
METHODS
Genotyping and subject recruitment. The study protocol and all experimental procedures were reviewed and approved by the local ethics committee for research on human subjects and conducted in accordance with the principles of the Declaration of Helsinki.
Blood samples for genotyping were obtained from 88 respondents to public advertisements seeking participants for this study. Genomic DNA was extracted from 3 ml fresh blood and used for the allelic identification of the Val158Met SNP (NCBI SNP-ID: rs4680) of the COMT gene.
Twenty-two young men (age range: 20-29 years) were selected on the basis of their Val158Met genotype, and they were paid for participating in the study. Ten were homozygous Val/Val allele carriers, and 12 were homozygous Met/Met allele carriers. The two groups were carefully matched for age, body mass index, habitual alcohol and caffeine consumption, anxiety (Trait Anxiety Inventory 44 ), subjective daytime sleepiness (Epworth Sleepiness Scale 45 ), and chronotype (Horne-Östberg Morningness-Eveningness Questionnaire 46 and Munich ChronoType Questionnaire 47 ). All screening and pre-experimental procedures, as well as the sleep and sleep deprivation protocol, were similar to or adapted from previous studies (see Supplementary Data online and refs. 26,48 for details).
Modafinil capsules and quantification of modafinil concentration in saliva. Two doses of 100 mg modafinil, in the form of capsules, were administered to all subjects after 11 and 23 h of prolonged wakefulness according to a randomized, double-blind, placebo-controlled, crossover design. The capsules were produced by homogenizing commercial Modasomil 100 tablets (distribution: Globopharm AG, Küsnacht, Switzerland) with mannitol (manufacturer: Siegfried Ltd., Zofingen, Switzerland). Placebo capsules of identical appearance contained only mannitol.
Saliva samples for modafinil quantification were collected in 15-ml centrifuge tubes (Techno Plastic Products AG, Trasadingen, Switzerland) immediately before administration of the first capsule and at defined time points during prolonged wakefulness. The samples were stored at −80 °C for later analyses with a novel liquid chromatography-mass spectrometry/mass spectrometry method developed in our institute (see Supplementary Data and Supplementary Table S1 online).
Subjective state and cognitive performance. At 16:45 hours on days 1 and 2 of prolonged wakefulness, subjects completed a Profile of Mood States given in the form of a validated German translation 23 and at 10:45 hours, von Zerssen's Befindlichkeits-Skala for objective evaluation of subjective well-being was administered. 24 Four hours after ingesting the capsule, the participants filled in a 20-item questionnaire about the subjective stimulant effects of the drug. This scale was developed by our group for previous investigations on the effects of caffeine during sleep deprivation. 48 Possible answers to the questions relating to whether common effects of stimulants were present or not were "not at all" (scored as 0), "a little" (1), "quite a bit" (2), and "very much" (3) (total score: 0-60).
In each study block, the participants completed 14 sessions of cognitive testing at 3-h intervals during a prolonged 40-h waking period. Each session consisted of a random-number-generation task 26, 49 preceded by a PVT 17 (for detailed information, see Supplementary Data online). On the eve of the adaptation night in each block, the subjects completed the tasks once to familiarize themselves with them.
A verbal two-back task to quantify working memory function was administered at 14:45 hours on days 1 and 2 of prolonged wakefulness. Performance on a task of an intermediate level of difficulty (two-back) was recently shown to be enhanced by 200 mg modafinil after overnight sleep deprivation. 36 All-night polysomnography. Continuous all-night polysomnographic recordings were performed each night. The EEG (data of derivation C3A2 are reported here), electro-oculogram, mental electromyogram, and electrocardiogram were recorded using Rembrandt DataLab (version 8; Embla Systems, Broomfield, CO) and the polygraphic amplifier Artisan (Micromed, Mogliano Veneto, Italy). Analog signals were conditioned by a high-pass filter (EEG: −3 dB at 0.15 Hz; electromyogram: 10 Hz; electrocardiogram: 1 Hz) and an anti-aliasing low-pass filter (−3 dB at 67.2 Hz), digitized and transmitted via fiber optic cables to a personal computer. Data were sampled at a frequency of 256 Hz. The sleep stages were visually scored for 20-s epochs according to standard criteria, 50 using Rembrandt Analysis Manager (version 8; Embla Systems, Broomfield, CO). The EEG power spectra of consecutive 20-s
